[go: up one dir, main page]

DE60005940D1 - Zusammensetzung zur behandlung sexueller funktionsstörungen die phosphodiesterase-5 inhibitoren enthaltend - Google Patents

Zusammensetzung zur behandlung sexueller funktionsstörungen die phosphodiesterase-5 inhibitoren enthaltend

Info

Publication number
DE60005940D1
DE60005940D1 DE60005940T DE60005940T DE60005940D1 DE 60005940 D1 DE60005940 D1 DE 60005940D1 DE 60005940 T DE60005940 T DE 60005940T DE 60005940 T DE60005940 T DE 60005940T DE 60005940 D1 DE60005940 D1 DE 60005940D1
Authority
DE
Germany
Prior art keywords
inhibitors
treatment
composition
functional disorders
disorders containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60005940T
Other languages
English (en)
Other versions
DE60005940T2 (de
DE60005940T3 (de
Inventor
Ernest Pullman
Steven Whitaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lilly Icos LLC
Original Assignee
Lilly Icos LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60005940(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos LLC filed Critical Lilly Icos LLC
Application granted granted Critical
Publication of DE60005940D1 publication Critical patent/DE60005940D1/de
Publication of DE60005940T2 publication Critical patent/DE60005940T2/de
Publication of DE60005940T3 publication Critical patent/DE60005940T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Formation And Processing Of Food Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
DE60005940.5T 1999-04-30 2000-04-26 Zusammensetzung zur behandlung sexueller funktionsstoerungen die phosphodiesterase-5 inhibitoren enthaltend Expired - Lifetime DE60005940T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13203699P 1999-04-30 1999-04-30
US132036P 1999-04-30
EP00926367.4A EP1173181B3 (de) 1999-04-30 2000-04-26 Zusammensetzung zur behandlung sexueller funktionsst?rungen die phosphodiesterase-5 inhibitoren enthaltend
PCT/US2000/011129 WO2000066099A2 (en) 1999-04-30 2000-04-26 Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction

Publications (3)

Publication Number Publication Date
DE60005940D1 true DE60005940D1 (de) 2003-11-20
DE60005940T2 DE60005940T2 (de) 2004-07-29
DE60005940T3 DE60005940T3 (de) 2015-08-27

Family

ID=22452153

Family Applications (3)

Application Number Title Priority Date Filing Date
DE20007861U Expired - Lifetime DE20007861U1 (de) 1999-04-30 2000-04-26 Hergestellte Artikel mit Phosphodiesterase-Inhibitor
DE60005940.5T Expired - Lifetime DE60005940T3 (de) 1999-04-30 2000-04-26 Zusammensetzung zur behandlung sexueller funktionsstoerungen die phosphodiesterase-5 inhibitoren enthaltend
DE10021266A Withdrawn DE10021266A1 (de) 1999-04-30 2000-04-26 Hergestellte Artikel mit Phosphodiesterase-Inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE20007861U Expired - Lifetime DE20007861U1 (de) 1999-04-30 2000-04-26 Hergestellte Artikel mit Phosphodiesterase-Inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE10021266A Withdrawn DE10021266A1 (de) 1999-04-30 2000-04-26 Hergestellte Artikel mit Phosphodiesterase-Inhibitor

Country Status (47)

Country Link
EP (2) EP1173181B3 (de)
JP (2) JP4975214B2 (de)
KR (2) KR20010020779A (de)
CN (2) CN1196487C (de)
AT (1) ATE251908T1 (de)
AU (3) AU769946C (de)
BE (1) BE1012957A5 (de)
BR (2) BR0010181A (de)
CA (2) CA2307101C (de)
CH (2) CH1173181H1 (de)
CO (1) CO5170493A1 (de)
CZ (1) CZ296534B6 (de)
DE (3) DE20007861U1 (de)
DK (2) DK200000677A (de)
DZ (1) DZ3171A1 (de)
EA (2) EA005416B1 (de)
ES (2) ES2187234A1 (de)
FI (1) FI20000976L (de)
FR (1) FR2795646B1 (de)
GB (1) GB2351663A (de)
GR (1) GR1003575B (de)
HK (1) HK1041204B (de)
HR (2) HRP20000243A2 (de)
HU (2) HUP0001632A3 (de)
ID (1) ID25704A (de)
IE (1) IE20000315A1 (de)
IL (3) IL135817A0 (de)
IT (1) ITMI20000922A1 (de)
LT (1) LT4758B (de)
LU (1) LU90569B1 (de)
LV (1) LV12560B (de)
MX (2) MXPA00003997A (de)
NL (1) NL1015027C2 (de)
NO (2) NO20002097L (de)
NZ (2) NZ514882A (de)
PE (1) PE20010071A1 (de)
PL (2) PL197813B1 (de)
PT (2) PT102457A (de)
SE (1) SE0001518L (de)
SG (1) SG98384A1 (de)
SI (2) SI1173181T1 (de)
SK (1) SK285415B6 (de)
SV (1) SV2002000055A (de)
TR (1) TR200001132A2 (de)
UA (1) UA72248C2 (de)
WO (1) WO2000066099A2 (de)
ZA (2) ZA200002058B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6841167B1 (en) * 1999-08-03 2005-01-11 Lilly Icos Llc. β-carboline pharmaceutical compositions
DE10010612A1 (de) * 2000-03-03 2001-09-27 Merck Patent Gmbh Verwendung von PDE V-Inhibitoren
EP1289990A1 (de) * 2000-06-08 2003-03-12 Lilly Icos LLC Tetrazyklische diketopierazin verbidnungen als pdev inhibitoren
AU2001271948A1 (en) 2000-08-02 2002-02-13 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
ATE360422T1 (de) 2001-06-05 2007-05-15 Lilly Icos Llc Tetrazyklische verbindungen als pde5-inhibitoren
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN102846585A (zh) * 2006-03-28 2013-01-02 杰佛林制药公司 低剂量的双氯芬酸和β-环糊精的制剂
US7495024B2 (en) 2006-08-07 2009-02-24 Via Pharmaceuticals, Inc. Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110263606A1 (en) * 2010-04-26 2011-10-27 Horst Zerbe Solid oral dosage forms comprising tadalafil
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
KR20150056443A (ko) 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
KR102646431B1 (ko) 2017-09-29 2024-03-12 한미약품 주식회사 생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
CA3091597A1 (en) * 2018-02-07 2019-08-15 Smawa Gmbh Pharmaceutical formulations, method for producing a pharmaceutical formulation, and medicament comprising same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
TR199802282T2 (xx) 1996-05-10 1999-03-22 Icos Corporation Karbolin t�revleri.
IL132276A0 (en) * 1997-04-25 2001-03-19 Pfizer Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cgmp pde5) for the treatment of sexual dysfunction
WO1999059584A1 (en) * 1998-05-20 1999-11-25 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
AU1025899A (en) 1998-09-16 2000-04-03 Icos Corporation Carboline derivatives as cgmp phosphodiesterase inhibitors
CA2346350C (en) * 1998-10-05 2008-01-08 Eisai Co., Ltd. Intraoral quickly disintegrating tablets
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6613768B1 (en) * 1999-04-30 2003-09-02 Lilly Icos Llc Treatment of female arousal disorder

Also Published As

Publication number Publication date
DE60005940T2 (de) 2004-07-29
EA200000355A2 (ru) 2000-10-30
DE60005940T3 (de) 2015-08-27
EP1415652A2 (de) 2004-05-06
MXPA01010837A (es) 2002-11-07
SI1173181T1 (en) 2004-04-30
JP2000336043A (ja) 2000-12-05
ES2208317T7 (es) 2015-09-15
FI20000976A0 (fi) 2000-04-26
NO20015275L (no) 2001-12-06
IL135817A0 (en) 2001-05-20
CH692478A5 (de) 2002-07-15
CZ20013879A3 (cs) 2002-04-17
HUP0200912A3 (en) 2003-07-28
HUP0001632A2 (hu) 2001-05-28
SK15632001A3 (sk) 2002-02-05
NZ504163A (en) 2001-11-30
IL146098A (en) 2007-06-03
PE20010071A1 (es) 2001-03-22
EA200101008A1 (ru) 2002-04-25
HU0200912D0 (en) 2002-04-29
BE1012957A5 (fr) 2001-06-05
HK1041204B (zh) 2004-03-05
NO20002097D0 (no) 2000-04-25
SK285415B6 (sk) 2007-01-04
EP1173181B1 (de) 2003-10-15
KR20020008396A (ko) 2002-01-30
WO2000066099A3 (en) 2001-01-18
IE20000315A1 (en) 2001-03-07
EP1173181B3 (de) 2015-03-25
ES2187234A1 (es) 2003-05-16
HRP20000243A2 (en) 2001-12-31
AU769946B2 (en) 2004-02-12
CN1384746A (zh) 2002-12-11
DK1173181T6 (en) 2015-04-27
MXPA00003997A (es) 2002-03-08
PL197813B1 (pl) 2008-04-30
PL352629A1 (en) 2003-08-25
LU90569B1 (fr) 2002-02-27
CA2307101A1 (en) 2000-10-30
HU230369B1 (hu) 2016-03-29
BR0010181A (pt) 2003-02-25
CN1196487C (zh) 2005-04-13
KR100577057B1 (ko) 2006-05-10
TR200001132A3 (tr) 2001-01-22
JP2002543116A (ja) 2002-12-17
GR1003575B (el) 2001-05-14
ZA200108900B (en) 2003-03-26
DE10021266A1 (de) 2000-11-16
SE0001518L (sv) 2000-10-31
DK200000677A (da) 2000-10-31
GB2351663A (en) 2001-01-10
CN1292264A (zh) 2001-04-25
FI20000976L (fi) 2000-10-30
NO20002097L (no) 2001-10-26
PT1173181E (pt) 2004-02-27
LT2000035A (lt) 2000-11-27
PL339897A1 (en) 2000-11-06
FR2795646B1 (fr) 2002-08-16
KR20010020779A (ko) 2001-03-15
CO5170493A1 (es) 2002-06-27
EA200000355A3 (ru) 2001-02-26
DE20007861U1 (de) 2000-08-24
GR20000100153A (el) 2000-12-29
LV12560B (en) 2001-04-20
JP4975214B2 (ja) 2012-07-11
WO2000066099A2 (en) 2000-11-09
DK1173181T3 (da) 2004-02-16
SG98384A1 (en) 2003-09-19
EP1173181A2 (de) 2002-01-23
AU769946C (en) 2005-01-13
AU4490800A (en) 2000-11-17
SE0001518D0 (sv) 2000-04-26
AU2004201988A1 (en) 2004-06-10
DZ3171A1 (de) 2000-11-09
CZ296534B6 (cs) 2006-04-12
CA2371684C (en) 2007-10-23
HUP0200912A2 (en) 2002-08-28
NZ514882A (en) 2003-08-29
EP1415652A3 (de) 2004-05-12
CA2371684A1 (en) 2000-11-09
ITMI20000922A0 (it) 2000-04-26
CA2307101C (en) 2003-01-28
LV12560A (en) 2000-11-20
LT4758B (lt) 2001-02-26
BR0003046A (pt) 2002-07-23
NO322013B1 (no) 2006-08-07
ES2208317T3 (es) 2004-06-16
TR200001132A2 (tr) 2001-01-22
ID25704A (id) 2000-11-02
NO322013B3 (no) 2017-11-06
AU3012900A (en) 2000-11-02
ATE251908T1 (de) 2003-11-15
NL1015027C2 (nl) 2001-02-14
PT102457A (pt) 2000-11-30
CH1173181H1 (de) 2019-07-15
HRP20010778B1 (en) 2005-04-30
ZA200002058B (en) 2000-11-02
HK1041204A1 (en) 2002-07-05
HRP20010778A2 (en) 2002-12-31
UA72248C2 (en) 2005-02-15
SI20361A (sl) 2001-04-30
HUP0001632A3 (en) 2001-12-28
NL1015027A1 (nl) 2000-10-31
NO20015275D0 (no) 2001-10-29
FR2795646A1 (fr) 2001-01-05
SV2002000055A (es) 2002-07-03
IL146098A0 (en) 2002-07-25
HU0001632D0 (en) 2000-06-28
ITMI20000922A1 (it) 2001-10-26
GB0010199D0 (en) 2000-06-14
EA005416B1 (ru) 2005-02-24

Similar Documents

Publication Publication Date Title
DE60005940D1 (de) Zusammensetzung zur behandlung sexueller funktionsstörungen die phosphodiesterase-5 inhibitoren enthaltend
ATE245648T1 (de) 1h-pyrazolo(3,4-d)pyrimidine-4,6-dione als inhibitoren für die vermehrung von t-zellen
WO2001080860A3 (en) Daily treatment for erectile dysfunction using a pde5 inhibitor
GEP20094596B (en) Compositions comprising phosphodiesterase inhibitors for the treatment of sexual dysfunction

Legal Events

Date Code Title Description
8364 No opposition during term of opposition